224 related articles for article (PubMed ID: 33688929)
1. cMyBPC phosphorylation modulates the effect of omecamtiv mecarbil on myocardial force generation.
Mamidi R; Holmes JB; Doh CY; Dominic KL; Madugula N; Stelzer JE
J Gen Physiol; 2021 Jul; 153(7):. PubMed ID: 33688929
[TBL] [Abstract][Full Text] [Related]
2. Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C.
Mamidi R; Gresham KS; Li A; dos Remedios CG; Stelzer JE
J Mol Cell Cardiol; 2015 Aug; 85():262-72. PubMed ID: 26100051
[TBL] [Abstract][Full Text] [Related]
3. Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium.
Mamidi R; Li J; Gresham KS; Verma S; Doh CY; Li A; Lal S; Dos Remedios CG; Stelzer JE
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29030372
[TBL] [Abstract][Full Text] [Related]
4. Impact of the Myosin Modulator Mavacamten on Force Generation and Cross-Bridge Behavior in a Murine Model of Hypercontractility.
Mamidi R; Li J; Doh CY; Verma S; Stelzer JE
J Am Heart Assoc; 2018 Sep; 7(17):e009627. PubMed ID: 30371160
[TBL] [Abstract][Full Text] [Related]
5. Omecamtiv Mecarbil Slows Myosin Kinetics in Skinned Rat Myocardium at Physiological Temperature.
Kieu TT; Awinda PO; Tanner BCW
Biophys J; 2019 Jun; 116(11):2149-2160. PubMed ID: 31103235
[TBL] [Abstract][Full Text] [Related]
6. Effect of the Novel Myotrope Danicamtiv on Cross-Bridge Behavior in Human Myocardium.
Choi J; Holmes JB; Campbell KS; Stelzer JE
J Am Heart Assoc; 2023 Oct; 12(20):e030682. PubMed ID: 37804193
[TBL] [Abstract][Full Text] [Related]
7. Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity.
Bakkehaug JP; Kildal AB; Engstad ET; Boardman N; Næsheim T; Rønning L; Aasum E; Larsen TS; Myrmel T; How OJ
Circ Heart Fail; 2015 Jul; 8(4):766-75. PubMed ID: 26025342
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Myosin Binding Protein-C Phosphorylation Modulates Myofilament Length-Dependent Activation.
Mamidi R; Gresham KS; Verma S; Stelzer JE
Front Physiol; 2016; 7():38. PubMed ID: 26913007
[TBL] [Abstract][Full Text] [Related]
9. The HCM-causing Y235S cMyBPC mutation accelerates contractile function by altering C1 domain structure.
Doh CY; Li J; Mamidi R; Stelzer JE
Biochim Biophys Acta Mol Basis Dis; 2019 Mar; 1865(3):661-677. PubMed ID: 30611859
[TBL] [Abstract][Full Text] [Related]
10. cMyBPC phosphorylation alters response to heart failure drug.
Short B
J Gen Physiol; 2021 Jul; 153(7):. PubMed ID: 34125165
[TBL] [Abstract][Full Text] [Related]
11. Dilated cardiomyopathy mutation in the converter domain of human cardiac myosin alters motor activity and response to omecamtiv mecarbil.
Tang W; Unrath WC; Desetty R; Yengo CM
J Biol Chem; 2019 Nov; 294(46):17314-17325. PubMed ID: 31578282
[TBL] [Abstract][Full Text] [Related]
12. Cardiac myosin binding protein-C Ser
Mamidi R; Gresham KS; Li J; Stelzer JE
Sci Adv; 2017 Mar; 3(3):e1602445. PubMed ID: 28345052
[TBL] [Abstract][Full Text] [Related]
13. In vivo cardiac myosin binding protein C gene transfer rescues myofilament contractile dysfunction in cardiac myosin binding protein C null mice.
Merkulov S; Chen X; Chandler MP; Stelzer JE
Circ Heart Fail; 2012 Sep; 5(5):635-44. PubMed ID: 22855556
[TBL] [Abstract][Full Text] [Related]
14. The energy-saving effect of a new myosin activator, omecamtiv mecarbil, on LV mechanoenergetics in rat hearts with blood-perfused isovolumic contraction model.
Obata K; Morita H; Takaki M
Naunyn Schmiedebergs Arch Pharmacol; 2019 Sep; 392(9):1065-1070. PubMed ID: 31267148
[TBL] [Abstract][Full Text] [Related]
15. Omecamtiv Mecarbil Enhances the Duty Ratio of Human β-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle.
Swenson AM; Tang W; Blair CA; Fetrow CM; Unrath WC; Previs MJ; Campbell KS; Yengo CM
J Biol Chem; 2017 Mar; 292(9):3768-3778. PubMed ID: 28082673
[TBL] [Abstract][Full Text] [Related]
16. Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (-)-noradrenaline.
Dashwood A; Cheesman E; Wong YW; Haqqani H; Beard N; Hay K; Spratt M; Chan W; Molenaar P
Pharmacol Res Perspect; 2021 May; 9(3):e00760. PubMed ID: 33929079
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analyses of the inotropic compound omecamtiv mecarbil in rat and human cardiac preparations.
Rhoden A; Schulze T; Pietsch N; Christ T; Hansen A; Eschenhagen T
Am J Physiol Heart Circ Physiol; 2022 Mar; 322(3):H373-H385. PubMed ID: 35030072
[TBL] [Abstract][Full Text] [Related]
18. Omecamtiv Mecarbil Abolishes Length-Mediated Increase in Guinea Pig Cardiac Myofiber Ca
Gollapudi SK; Reda SM; Chandra M
Biophys J; 2017 Aug; 113(4):880-888. PubMed ID: 28834724
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil.
Planelles-Herrero VJ; Hartman JJ; Robert-Paganin J; Malik FI; Houdusse A
Nat Commun; 2017 Aug; 8(1):190. PubMed ID: 28775348
[TBL] [Abstract][Full Text] [Related]
20. The contribution of cardiac myosin binding protein-c Ser282 phosphorylation to the rate of force generation and in vivo cardiac contractility.
Gresham KS; Mamidi R; Stelzer JE
J Physiol; 2014 Sep; 592(17):3747-65. PubMed ID: 24951619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
